Top
Squamous cell carcinoma - Healing Genes
566
post-template-default,single,single-post,postid-566,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Squamous cell carcinoma

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine)

Phase I Trial Evaluating Genetically Modified Autologous T Cells Expressing a T-Cell Receptor Recognizing a Cancer/Germline Antigen in Patients Having Solid Tumors With Emphasis on NSCLC or HNSCC


Phase 1

DESCRIPTION:

Doctors at UT MD Anderson Cancer Center see participants with one of the following types of cancer to receive a clinical trial of a gene-modified immunotherapy treatment to redirect and activate the patient’s own T-cells to treat their cancer.

  • Solid Tumor
  • Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Non-small Cell Lung Cancer

The therapy removes the patient’s immune cells and utilizes genetic engineering to activate those cells to recognize their cancer as a target. After multiplying the cells in the lab, they are re-infused to the patient after a cycle of chemotherapy. An additional drug, interleukin-2, will also be administered to encourage the growth of the T-cells. The first 12 months most treatment will require regular assessments (lab and other types), and the patient will be tracked for up to 15 years from the last treatment.


PATIENT MUST:

  • Meet pathology screenings related to their cancer type/diagnosis
  • Have at least one lesion (tumor) able to be biopsied
  • Have normal liver function
  • Meet required levels of lung, clotting, and immune system function
  • Not have a serious autoimmune disease

THE STUDY INVOLVES:

  1. Screening of the patient’s human leukocyte antigen (HLA) profile for appropriate fit to the study’s needs.
  2. Leukapheresis to extract the patient’s white blood cells from their blood, which is then used for creation of the genetically engineered and amplified product.
  3. Chemotherapy to deplete the patient’s remaining immune cells before the engineered product is returned to the patient via transfusion.
  4. Each participant will be followed for 12 months to track their T-cell levels and T-cell activity as well as overall clinical response of their tumor.
  5. Follow-up post the first 12 months will be less intensive but continue for at least 15 years.

LOCATIONS AND CONTACTS:

University of Texas MD Anderson Cancer Center in Houston, TX is recruiting participants for this study. Map

Contact: Rebecca Griffith-Eskew  |  [email protected]  |  346-204-5359


SPONSOR INFORMATION:

Immatics US, Inc. & M.D. Anderson Cancer Center

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03247309

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader